How does the Anti-HIgG(Fab)-N-MMAF ADC specifically target and eliminate tumor cells?

The ADC utilizes a Fab fragment to specifically bind to human IgG present on certain tumor cells. Once bound, the ADC is internalized, allowing the non-cleavable linker to release MMAF within the cell, where it disrupts tubulin polymerization, effectively halting cell division and leading to cell death.

How does Creative Biolabs assess the specificity of the Anti-HIgG(Fab)-N-MMAF ADC towards human IgG?

Creative Biolabs employs various in vitro assays to measure the binding specificity of the ADC, including enzyme-linked immunosorbent assays (ELISA) and surface plasmon resonance (SPR). These assays help confirm that the ADC effectively recognizes and binds to human IgG with high specificity.

What experimental evidence supports the efficacy of the Anti-HIgG(Fab)-N-MMAF ADC in preclinical studies?

Creative Biolabs provides data from cell viability assays, flow cytometry, and apoptosis assays that demonstrate the ADC's ability to selectively kill cancer cells expressing human IgG. This evidence is crucial for validating the ADC's potential use in targeted cancer therapy.

How does the Anti-HIgG(Fab)-N-MMAF ADC maintain its stability and efficacy during storage and handling?

The stability and efficacy of the Anti-HIgG(Fab)-N-MMAF ADC are maintained through optimized formulation and storage conditions, typically requiring refrigeration and protection from light. Creative Biolabs provides specific guidelines on handling practices to prevent degradation and preserve the ADC's functional integrity.

Can the Anti-HIgG(Fab)-N-MMAF ADC be integrated into multimodal treatment regimens for cancer therapy?

Yes, the Anti-HIgG(Fab)-N-MMAF ADC can be integrated into multimodal treatment plans, potentially being used in combination with radiotherapy, immunotherapy, or other chemotherapy agents.

Home
Products
Anti-Ab ADCs
IgG Fab
Anti-HIgG(Fab)-N-MMAF ADC

Anti-HIgG(Fab)-N-MMAF ADC (CAT#: ADC-AA-063)

This ADC product is comprised of an anti-human IgG Fab-specific polyclonal antibody conjugated via a non-cleavable linker to MMAF.The antibody portion is a secondary antibody. Monomethyl auristatin F (MMAF) is a cytotoxic small molecule which inhibits cell division by blocking the polymerization of tubulin.

ADC Target
ADC Antibody
ADC Linker
ADC payload drug

Overview
The fragment antigen-binding (Fab) fragment is a region on an antibody that binds to antigens. It is composed of one constant and one variable domain of each of the heavy and the light chain. The variable domain contains the paratope (the antigen-binding site), comprising a set of complementarity determining regions, at the amino terminal end of the monomer. Each arm of the Y thus binds an epitope on the antigen.

Overview
Anti-human IgG Fab-specific polyclonal antibody

Species Reactivity
Human

Name
Noncleavable linkers

Description
Noncleavable linkers, is considered noncleavable-meaning linker cleavage, and payload release does not depend on the differential properties between the plasma and some cytoplasmic compartments. Instead, the release of the cytotoxic drug is postulated to

Name
MMAF

Description
Derived from Auristatin,are water-soluble dolastatin analogs of dolastatin 10. Dolastatin 10 belongs to dolastatin family and it can powerfully bind to tubulin, thus inhibiting polymerization mediated through the binding to the vinca alkaloid binding domain, and causes cell to accumulate in metaphase arrest.

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-AA-063. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

The Anti-HIgG(Fab)-N-MMAF ADC has greatly improved our research outcomes. The combination of Fab targeting and MMAF's potent cytotoxicity has delivered excellent results. An indispensable product!

Excellent

The Anti-HIgG(Fab)-N-MMAF ADC from Creative Biolabs has proven to be an essential part of our research. Its targeted action and strong cytotoxicity have produced highly reliable results. Highly recommend!

Excellent

The Anti-HIgG(Fab)-N-MMAF ADC from Creative Biolabs delivers top-notch performance. Its precise targeting and powerful cytotoxicity have significantly advanced our studies. Highly satisfied!

Excellent

The Anti-HIgG(Fab)-N-MMAF ADC is a must-have for anyone working in targeted therapies. Its combination of Fab specificity and MMAF cytotoxicity provides outstanding results. Extremely pleased with this product!

Excellent

The Anti-HIgG(Fab)-N-MMAF ADC has exceeded our expectations in precision and effectiveness. Its targeted delivery and potent cytotoxicity have made it an invaluable tool in our research.

Q: 1: How does the Anti-HIgG(Fab)-N-MMAF ADC specifically target and eliminate tumor cells?
A: The ADC utilizes a Fab fragment to specifically bind to human IgG present on certain tumor cells. Once bound, the ADC is internalized, allowing the non-cleavable linker to release MMAF within the cell, where it disrupts tubulin polymerization, effectively halting cell division and leading to cell death.
Q: 2: How does Creative Biolabs assess the specificity of the Anti-HIgG(Fab)-N-MMAF ADC towards human IgG?
A: Creative Biolabs employs various in vitro assays to measure the binding specificity of the ADC, including enzyme-linked immunosorbent assays (ELISA) and surface plasmon resonance (SPR). These assays help confirm that the ADC effectively recognizes and binds to human IgG with high specificity.
Q: 3: What experimental evidence supports the efficacy of the Anti-HIgG(Fab)-N-MMAF ADC in preclinical studies?
A: Creative Biolabs provides data from cell viability assays, flow cytometry, and apoptosis assays that demonstrate the ADC's ability to selectively kill cancer cells expressing human IgG. This evidence is crucial for validating the ADC's potential use in targeted cancer therapy.
Q: 4: How does the Anti-HIgG(Fab)-N-MMAF ADC maintain its stability and efficacy during storage and handling?
A: The stability and efficacy of the Anti-HIgG(Fab)-N-MMAF ADC are maintained through optimized formulation and storage conditions, typically requiring refrigeration and protection from light. Creative Biolabs provides specific guidelines on handling practices to prevent degradation and preserve the ADC's functional integrity.
Q: 5: Can the Anti-HIgG(Fab)-N-MMAF ADC be integrated into multimodal treatment regimens for cancer therapy?
A: Yes, the Anti-HIgG(Fab)-N-MMAF ADC can be integrated into multimodal treatment plans, potentially being used in combination with radiotherapy, immunotherapy, or other chemotherapy agents.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Other Products

Same Target Same Linker Same Payload

CAT#	Product Name	Linker	Payload
ADC-AA-018	anti-HIgG(Fab)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-064	Anti-HIgG(Fab)-C-MMAF ADC	Cleavable linkers	MMAF
ADC-AA-017	anti-HIgG(Fab)-C-MMAE ADC	Cleavable linkers	MMAE (Monomethyl auristatin E)

CAT#	Product Name	Linker	Payload
ADC-AA-008	anti-HIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-037	anti-RIgG(HL)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-026	anti-MIgG(Fc)-N-DM1 ADC	Noncleavable linkers	DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine)
ADC-AA-027	anti-MIgG(Fc)Fab-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)
ADC-AA-039	anti-Rat IgG(Fc)-N-MMAF ADC	Noncleavable linkers	MMAF (Monomethyl auristatin F)

CAT#	Product Name	Linker	Payload
ADC-W-2579	Anti-CEACAM5-MC-MMAF ADC	MC (maleimidocaproyl)	MMAF
ADC-W-2612	Anti-MS4A1 (Rituximab)-MC-MMAF ADC	MC (maleimidocaproyl)	MMAF
ADC-W-2561	Anti-MSLN (Anetumab )-MC-MMAF ADC	MC (maleimidocaproyl)	MMAF
ADC-AA-064	Anti-HIgG(Fab)-C-MMAF ADC	Cleavable linkers	MMAF
ADC-W-2567	Anti-MUC16 (Sofituzumab)-MC-MMAF ADC	MC (maleimidocaproyl)	MMAF

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.